• HREC approval received to conduct Phase IIa clinical trial of Xolatryp in heart attack patients
• Preclinical studies initiated to assess Xolatryp's efficacy in oncology indications
• Sound financial position with AU$6.74 million cash balance

Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors, has announced its Quarterly Activities Report and Appendix 4C for the three months ending 31 March 2026. Key highlights include:Xolatryp® Program Phase IIa Clinical Trial: Nyrada received Human Research Ethics Committee (HREC) approval to conduct a Phase IIa clinical trial to assess the safety and preliminary efficacy of Xolatryp® in heart attack patients undergoing angioplasty with stenting. Patient recruitment will commence in April 2026.Research and Development: Nyrada initiated preclinical studies to assess the efficacy of Xolatryp across oncology indications, including its potential to provide cardioprotection against anthracycline-induced cardiotoxicity.Patent: Nyrada's composition of matter patent application was published, which will provide 20 years of intellectual property protection from the priority date.Finance, Capital and Corporate: Nyrada had a cash position of AU$6.74 million as of 31 March 2026 and expects to receive an R&D tax rebate of AU$2.45 million for the financial year ended 30 June 2025.